127 related articles for article (PubMed ID: 35846513)
1. Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2.
Wnorowska S; Targowska-Duda K; Kurzepa J; Wnorowski A; Strzemski M
Ind Crops Prod; 2022 Nov; 187():115338. PubMed ID: 35846513
[No Abstract] [Full Text] [Related]
2. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Evaluation of the Antibacterial and Antifungal Activities of
Rosato A; Barbarossa A; Mustafa AM; Bonacucina G; Perinelli DR; Petrelli R; Maggi F; Spinozzi E
Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943662
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
5.
Tiwari V
Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
[TBL] [Abstract][Full Text] [Related]
6. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of Carlina Oxide-A Natural Polyacetylene from the
Wnorowski A; Wnorowska S; Wojas-Krawczyk K; Grenda A; Staniak M; Michalak A; Woźniak S; Matosiuk D; Biała G; Wójciak M; Sowa I; Krawczyk P; Strzemski M
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283677
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors.
Singh R; Bhardwaj VK; Sharma J; Kumar D; Purohit R
Comput Biol Med; 2021 Sep; 136():104631. PubMed ID: 34273770
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
[TBL] [Abstract][Full Text] [Related]
10. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
11. Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 binding.
Invernizzi L; Moyo P; Cassel J; Isaacs FJ; Salvino JM; Montaner LJ; Tietjen I; Maharaj V
Anal Bioanal Chem; 2022 May; 414(13):3971-3985. PubMed ID: 35419694
[TBL] [Abstract][Full Text] [Related]
12. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
Borkotoky S; Dey D; Hazarika Z
Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
14. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
15. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
16. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.
Basit A; Ali T; Rehman SU
J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773
[TBL] [Abstract][Full Text] [Related]
17. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
[TBL] [Abstract][Full Text] [Related]
18. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
[TBL] [Abstract][Full Text] [Related]
19. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
20. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
